Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price

Johnson & Johnson shares are up 24.03% year-to-date and 65.92% over the past year, supported by oncology strength and a raised full-year outlook. The article points to improving fundamentals from oncology rather than any near-term negative catalyst.

Analysis

Johnson & Johnson shares are up 24.03% year-to-date and 65.92% over the past year, supported by oncology strength and a raised full-year outlook. The article points to improving fundamentals from oncology rather than any near-term negative catalyst.